Company: BIAF
Filing Date: 2025-04-11
Form Type: S-1
Source: 0001641172-25-003892
Chunk: 2

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-11
Form: S-1
Chunk 2
---
 Common Stock issuable upon the exercise
of common warrants (the “Inducement Warrants”) to purchase 2,926,166 shares of Common Stock (the “Inducement Warrant
Shares”) issued to certain holders (the “Holders”) of existing warrants in a warrant inducement private placement transaction
(the “Warrant Inducement”) pursuant to the terms of a warrant inducement agreement, dated February 25, 2025 (the “Inducement
Agreement”) between us and the Holders; and (ii) 87,785 shares of Common Stock issuable upon the exercise of warrants (the “Advisor
Warrants”) to purchase 87,785 shares of Common Stock (the “Advisor Warrant Shares”) issued to designees of WallachBeth
Capital LLC (“WallachBeth”) issued as partial compensation for WallachBeth acting as financial advisor in connection with
the Warrant Inducement. The Warrant Inducement closed on February 26, 2025. The Holders and the designees of WallachBeth that received
Advisor Warrants are collectively referred to herein as the “Selling Stockholders.” The Inducement Warrants and the Advisor
Warrants are collectively referred to herein as the “Common Warrants.” The Inducement Warrant Shares and the Advisor Warrant
Shares are collectively referred to herein as the “Common Warrant Shares.”

We are filing this registration statement on Form
S-1, of which this prospectus forms a part, to fulfill our contractual obligations to provide for the registration of the resale of the
Inducement Warrant Shares by the Holders, as well as to provide for the registration of the resale of the Placement Agent Warrant Shares
by the designees of WallachBeth. See “Selling Stockholders” beginning on page 41 of this prospectus for more information
about the Selling Stockholders. The registration of the shares of Common Stock to which this prospectus relates does not require the Selling
Stockholders to sell any of their shares of our Common Stock.

We are not offering any shares of Common Stock under
this prospectus and will not receive any proceeds from the sale or other disposition of the shares of our Common Stock covered hereby.
However, we will receive the proceeds from any exercise of the Common Warrants for cash. See “Use of Proceeds” beginning on
page 38 of this prospectus.

The Selling Stockholders identified in this prospectus,
or their